142 related articles for article (PubMed ID: 22208962)
1. PET/CT in anal cancer - is it worth doing?
Wells IT; Fox BM
Clin Radiol; 2012 Jun; 67(6):535-40. PubMed ID: 22208962
[TBL] [Abstract][Full Text] [Related]
2. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
[TBL] [Abstract][Full Text] [Related]
3. Role of positron emission tomography-computed tomography in the management of anal cancer.
Mistrangelo M; Pelosi E; Bellò M; Ricardi U; Milanesi E; Cassoni P; Baccega M; Filippini C; Racca P; Lesca A; Munoz FH; Fora G; Skanjeti A; Cravero F; Morino M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):66-72. PubMed ID: 22592047
[TBL] [Abstract][Full Text] [Related]
4. The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis.
Jones M; Hruby G; Solomon M; Rutherford N; Martin J
Ann Surg Oncol; 2015 Oct; 22(11):3574-81. PubMed ID: 25652048
[TBL] [Abstract][Full Text] [Related]
5. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography/computed tomography in the staging and treatment of anal cancer.
Sveistrup J; Loft A; Berthelsen AK; Henriksen BM; Nielsen MB; Engelholm SA
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):134-41. PubMed ID: 22000745
[TBL] [Abstract][Full Text] [Related]
7. To PET or not to PET? That is the question. Staging in anal cancer.
Bhuva NJ; Glynne-Jones R; Sonoda L; Wong WL; Harrison MK
Ann Oncol; 2012 Aug; 23(8):2078-2082. PubMed ID: 22294527
[TBL] [Abstract][Full Text] [Related]
8. FDG PET/CT in the management of colorectal and anal cancers.
Agarwal A; Marcus C; Xiao J; Nene P; Kachnic LA; Subramaniam RM
AJR Am J Roentgenol; 2014 Nov; 203(5):1109-19. PubMed ID: 25341152
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET/CT in the evaluation of anal carcinoma.
Cotter SE; Grigsby PW; Siegel BA; Dehdashti F; Malyapa RS; Fleshman JW; Birnbaum EH; Wang X; Abbey E; Tan B; Kodner IJ; Hunt SR; Lowney JK; Mutch MG; Dietz DW; Myerson RJ
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):720-5. PubMed ID: 16626889
[TBL] [Abstract][Full Text] [Related]
10. Positron-emission tomography/computed tomography (PET/CT) in the initial staging of primary rectal cancer.
Eglinton T; Luck A; Bartholomeusz D; Varghese R; Lawrence M
Colorectal Dis; 2010 Jul; 12(7):667-73. PubMed ID: 19486092
[TBL] [Abstract][Full Text] [Related]
11. Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival.
Deantonio L; Milia ME; Cena T; Sacchetti G; Perotti C; Brambilla M; Turri L; Krengli M
Radiol Med; 2016 Jan; 121(1):54-9. PubMed ID: 26126968
[TBL] [Abstract][Full Text] [Related]
12. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma.
Vercellino L; Montravers F; de Parades V; Huchet V; Kerrou K; Bauer P; Touboul E; Talbot JN
Int J Colorectal Dis; 2011 Feb; 26(2):201-10. PubMed ID: 21061012
[TBL] [Abstract][Full Text] [Related]
13. Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer.
Teagle AR; Gilbert DC; Jones JR; Burkill GJ; McKinna F; Dizdarevic S
Nucl Med Commun; 2016 Oct; 37(10):1038-45. PubMed ID: 27341410
[TBL] [Abstract][Full Text] [Related]
14. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
15. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
16. Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up.
Quartuccio N; Fox J; Kuk D; Wexler LH; Baldari S; Cistaro A; Schöder H
AJR Am J Roentgenol; 2015 Jan; 204(1):153-60. PubMed ID: 25539251
[TBL] [Abstract][Full Text] [Related]
17. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
[TBL] [Abstract][Full Text] [Related]
18. Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
Piperkova E; Raphael B; Altinyay M; Castellon I; Libes R; Sandella N; Abdel-Dayem H
J BUON; 2006; 11(4):523-7. PubMed ID: 17309188
[TBL] [Abstract][Full Text] [Related]
19. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
Winton Ed; Heriot AG; Ng M; Hicks RJ; Hogg A; Milner A; Leong T; Fay M; MacKay J; Drummond E; Ngan SY
Br J Cancer; 2009 Mar; 100(5):693-700. PubMed ID: 19259091
[TBL] [Abstract][Full Text] [Related]
20. Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up.
Saboo SS; Zukotynski K; Shinagare AB; Krajewski KM; Ramaiya N
Abdom Imaging; 2013 Aug; 38(4):728-35. PubMed ID: 23011550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]